The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2020 contains several updates—including new and expanded sections on risk assessment and management related to three major cancer types—while also maintaining a more conservative approach toward testing practices where the evidence is still lacking. In the rapidly-moving field of cancer care and genetics, NCCN Guidelines® synthesize the latest evidence and expert consensus to ensure recommendations are firmly supported by quality research, in order to establish best management paradigms that improve outcomes for people with cancer. Read more . . .
The National Comprehensive Cancer Network® (NCCN®) today announced publication of the newest genetic risk assessment recommendations for breast, ovarian and pancreatic cancers.